MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

32.12 -2.04

Overview

Share price change

24h

Current

Min

31.79

Max

32.79

Key metrics

By Trading Economics

Income

-48M

-27M

Sales

3M

99M

EPS

-0.45

Profit margin

-27.41

Employees

979

EBITDA

3.2M

-21M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+16.49% upside

Market Stats

By TradingEconomics

Market Cap

275M

2.1B

Previous open

34.16

Previous close

32.12

News Sentiment

By Acuity

50%

50%

149 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

29 Dec 2025, 22:03 UTC

Major Market Movers

Mining Stocks Slip Near the End of Stellar Year

29 Dec 2025, 15:57 UTC

Major Market Movers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 Dec 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29 Dec 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Operate From Singapore

29 Dec 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 Dec 2025, 23:37 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Integrate Manus Service Into Products

29 Dec 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 Dec 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 Dec 2025, 23:35 UTC

Acquisitions, Mergers, Takeovers

Manus to Join Meta Platforms

29 Dec 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Raise Values Kraken at US$8.65 Billion

29 Dec 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 Dec 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 Dec 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 Dec 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin's Kraken Stake to Remain at 22.7%

29 Dec 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 Dec 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 Dec 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin: Additional Interest Offsets Dilution From Raise

29 Dec 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 Dec 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 Dec 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 Dec 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 Dec 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 Dec 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 Dec 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 Dec 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 Dec 2025, 21:27 UTC

Acquisitions, Mergers, Takeovers

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 Dec 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 Dec 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 Dec 2025, 20:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 Dec 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

16.49% upside

12 Months Forecast

Average 38.5 USD  16.49%

High 42 USD

Low 32 USD

Based on 5 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

149 / 374 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat